Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

The combination of tretinoin, minoxidil, and betamethasone valerate may cause severe scalp inflammation.

In this study, adding TPGS to a minoxidil formulation improved local retention and reduced systemic absorption in certain solvent mixes, particularly with a balance of alcohol and PEG 400.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

This open-label study found that oral tofacitinib led to significant hair regrowth in patients with moderate-to-severe alopecia areata, supported by changes in gene expression and T cell dynamics.

An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.

In this study, prolonged intravenous Fenoterol infusion was associated with intensive hair growth in most patients, although hormonal changes typically linked to such effects were not observed.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.

Tofacitinib may effectively treat folliculitis decalvans.

This case report highlights a 33-year-old female with systemic lupus erythematosus and refractory alopecia who experienced significant hair regrowth after treatment with tofacitinib, maintained even after glucocorticoid tapering over two years.

In this report, a 14-year-old female with stubborn alopecia areata was successfully treated with oral tofacitinib, indicating its potential effectiveness for severe cases.

This study found that treatment with oral tofacitinib, alone or with other therapies, was associated with clinical improvement in most patients with recalcitrant lichen planopilaris.

This review consolidates evidence on Croton tiglium's bioactive compounds and effects, discussing its potential uses in treatments like hair-growth formulations, yet emphasizes the significant safety challenges due to the plant's inherent toxicity.

This study found that topical application of TSG from Polygonum multiflorum promoted hair regrowth in depilated mice, potentially through the inhibition of apoptosis-related proteins.

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

Recombinant human TSG-6 speeds up wound healing in diabetic mice.

This study found that topical application of tideglusib in a bacterial cellulose-based hydrogel showed positive effects on the healing of palatal wounds in rats.

In this case series, dual-targeted therapy was observed to provide promising clinical responses in refractory inflammatory bowel disease, with 88.23% to 100% response rates across 9 months and an endoscopic response in 88.89% of evaluated patients, though some adverse events occurred.

Using finasteride with TIP extends time off period for prostate cancer patients.

This study found that tideglusib delivered topically in a bacterial cellulose hydrogel showed positive effects on the wound healing of rat palatal mucosa, as observed through macroscopic, histomorphometric, and immunohistochemical evaluations.

In this case report, a 39-year-old woman's symptoms from dermatomyositis–systemic lupus erythematosus overlap syndrome improved only after she was treated with tofacitinib.

This study reports that tofacitinib, a JAK 1/3 inhibitor, showed significant improvement in a patient with co-occurring severe alopecia totalis and lichen planus hypertrophicus, conditions that are typically resistant to treatment.

Tofacitinib partially improved hair regrowth in a patient with severe hair loss.

In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.

In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.